<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Parenteral nutrition in premature infants</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Parenteral nutrition in premature infants</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Parenteral nutrition in premature infants</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ian J Griffin, MB ChB</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven A Abrams, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2686617490"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Parenteral nutrition (PN) was first used in newborn infants almost 50 years ago [<a href="#rid1">1</a>]. Since then, it has proven to be a valuable, life-saving tool in preterm infants who are unable to tolerate sufficient enteral feeds to meet their nutritional needs. However, the limitations and toxicities of PN have become increasingly recognized. As a result, the practice of PN continues to evolve as new products and technologies become available.</p><p>The composition, prescription, and administration of PN to premature infants will be discussed here. The composition of and transition to enteral feedings is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant"</a>.)</p><p class="headingAnchor" id="H1149087813"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>For most preterm infants, PN should be considered as a short-term bridge to provide nutritional support until full enteral nutrition can be provided [<a href="#rid2">2</a>]. Such instances include:</p><p class="bulletIndent1"><span class="glyph">●</span>Immediately after birth – To provide essential nutrition as enteral feeds are commenced and advanced</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During periods of acute gastrointestinal malfunction (eg, due to septic ileus or necrotizing enterocolitis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When infants are felt to be "too sick" to receive enteral feeds (eg, during treatment with high-dose pressors or extracorporeal membrane oxygenation)</p><p></p><p>In a small subset of infants, prolonged periods of PN may be required. These infants typically have congenital or acquired gastrointestinal malformations, including short bowel syndrome. The risks associated with PN increase with the dose and duration of PN, so the goal of care should always be to move to full enteral nutrition as quickly as possible. (See  <a class="medical medical_review" href="/z/d/html/5894.html" rel="external">"Management of short bowel syndrome in children"</a> and  <a class="medical medical_review" href="/z/d/html/5948.html" rel="external">"Intestinal failure-associated liver disease in infants"</a>.)</p><p class="headingAnchor" id="H2785224454"><span class="h1">PARENTERAL NUTRITIONAL REQUIREMENTS</span></p><p class="headingAnchor" id="H3811106214"><span class="h2">Phases of parenteral nutrition</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early PN</strong> – This phase of PN is intended to be started as soon as possible after the infant's birth, usually within a few hours after delivery [<a href="#rid2">2</a>]. Its primary goal is to prevent excessive catabolism by providing energy and protein. Secondary goals include prevention of hypocalcemia. In this phase, PN usually contains only dextrose, amino acids and calcium, but not sodium, potassium, magnesium, or phosphorus  (<a class="graphic graphic_table graphicRef117237" href="/z/d/graphic/117237.html" rel="external">table 1</a>). Intravenous lipids can be included in the initial prescription, or added on the first or second day of life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Full PN</strong> – This phase of PN is intended to meet the entire nutritional needs of the infant and support normal rates of growth. To do so, it must contain a wide range of essential nutrients  (<a class="graphic graphic_table graphicRef117237" href="/z/d/graphic/117237.html" rel="external">table 1</a>), and sufficient protein and energy to support growth.</p><p></p><p>The transition from early to full PN should be accomplished as quickly as is tolerated. Ideally, the transition occurs within three days of birth, although this may not be possible if the infant does not tolerate the glucose or lipid infusion rates required to achieve the nutrient targets. Although energy intakes of 30 to 40 kcal/kg/day and protein intakes of 1 to 1.5 g/kg/day are probably sufficient to limit catabolism early in postnatal life, much higher energy intakes are needed to achieve near-normal rates of growth. Traditionally, protein and lipid intakes were slowly increased over the first few days of life, but there is evidence that slow advancement is not necessary in most cases. (See <a class="local">'Energy requirements'</a> below and <a class="local">'Amino acids'</a> below.)</p><p class="headingAnchor" id="H1560593923"><span class="h2">Energy requirements</span><span class="headingEndMark"> — </span>Early PN should contain 35 to 45 kcal/kg/day of nonprotein energy (or 45 to 60 kcal/kg/day of total energy)  (<a class="graphic graphic_table graphicRef117237" href="/z/d/graphic/117237.html" rel="external">table 1</a>). Subsequently, the energy intake should be increased as quickly as possible. In practice, this may be difficult in extremely preterm infants, who may not tolerate high intakes of carbohydrate or lipid.</p><p>Full PN should contain &gt;65 kcal/kg/day of nonprotein energy (or 80 to 90 kcal/kg/day of total energy) to allow normal growth rates [<a href="#rid3">3</a>]. This target for energy in PN is approximately 20 percent less than required for enterally fed infants. This is because enteral feeds are incompletely absorbed, and the processes of gastrointestinal digestion and absorption impose energy costs that are not present when nutrients are provided parenterally.</p><p class="headingAnchor" id="H2326771389"><span class="h2">Macronutrient balance</span><span class="headingEndMark"> — </span>Energy in PN can be provided as carbohydrates (as glucose), lipids, and protein (as amino acids). Each of these components is necessary to achieve growth.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucose</strong> – To avoid hypoglycemia and to meet the obligatory glucose needs of the developing brain, glucose should be provided at a minimum rate of 5 to 8 mg/kg/minute, starting immediately after birth (eg, 10% dextrose solution at 100 mL/kg/day). As PN is advanced, the glucose component is typically increased to around 12 to 15 mg/kg/minute, but the target rate may vary depending on the proportion of energy needs provided by lipids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lipids</strong> – Lipids should provide approximately 30 to 50 percent of nonprotein energy (similar to human milk), which may help to optimize protein accretion while limiting the potential toxicity of excessive lipids. As an example, in one study, PN containing either 29 or 40 percent of nonprotein energy as fat (equivalent to approximately 2 to 3 g/kg/day of lipid) resulted in improved protein retention compared with PN with a lower proportion of fat [<a href="#rid4">4</a>]. Similarly, in a separate study, PN containing 50 percent of nonprotein energy as lipid resulted in lower protein oxidation and protein turnover, compared with a lipid-free PN with similar energy and nitrogen content [<a href="#rid5">5</a>]. In theory, PN with a higher ratio of lipid might also improve oxygenation because it has a lower respiratory quotient (the ratio of carbon dioxide [CO<sub>2</sub>] produced: oxygen consumed). However, clinical studies have failed to substantiate this benefit. As an example, in one study that examined the effects of isoenergetic PN solutions differing in the relative amounts of fat and carbohydrate, the oxygen consumption did not vary with the macronutrient composition [<a href="#rid6">6</a>]. Although CO<sub>2</sub> production was higher in PN with a lower proportion of fat, there were no differences in partial pressure of carbon dioxide (PCO<sub>2</sub>), and partial pressure of oxygen (PO<sub>2</sub>) was higher. A possible explanation is that the higher lipid infusions adversely affected alveolar function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protein</strong> – If sufficient energy cannot be provided due to lipid or glucose intolerance in the very low birth weight (VLBW) infant, providing the "target" intake of amino acid/protein will not achieve normal growth; rather, it will impose a metabolic burden on the infant as amino acids need to be catabolized. For this reason, protein requirements and nonprotein energy requirements are not independent but interlinked.</p><p></p><p class="headingAnchor" id="H3658007476"><span class="h2">Amino acids</span><span class="headingEndMark"> — </span>We suggest starting amino acids as soon as possible after birth (ie, within a few hours of birth). Early initiation of PN including amino acids for preterm infants is associated with improved short-term growth outcomes (such as the time to regain birth weight) and medium-term growth outcomes (such as discharge weight or length below the 10<sup>th</sup> percentile for age) compared with later initiation of PN [<a href="#rid7">7</a>]. Amino acid intakes as low as 1.0 to 1.5 g/kg/day appear sufficient to prevent overt catabolism, which is associated negative nitrogen balance [<a href="#rid8">8</a>] and risk of hyperkalemia [<a href="#rid9">9</a>]. Higher intakes are required to support growth that approximates in utero accretion rates.</p><p>Our suggested target depends on the infant's weight:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>VLBW infants</strong> – For VLBW infants (birth weight 1000 to 1500 g), amino acids are usually started at 1.5 to 2.5 g/kg/day and then advanced rapidly to reach a target of 3.5 g/kg/day by the second or third day of life  (<a class="graphic graphic_table graphicRef117237" href="/z/d/graphic/117237.html" rel="external">table 1</a>) [<a href="#rid2">2,3</a>]. These intakes of amino acids are associated with improved nitrogen retention [<a href="#rid8">8</a>] and reduced rates of hyperglycemia [<a href="#rid10">10</a>] compared with lower intakes of amino acids. In some neonatal intensive care units, amino acid intakes are increased more slowly, eg, by 0.5 g/kg/day each day, but there is no evidence that this slow advancement is beneficial. Our recommendations for VLBW infants are consistent with a European guideline [<a href="#rid11">11</a>] and supported by most literature [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1">Of note, adequate nonprotein energy intake (approximately 65 kcal/kg/day) is also required for optimum protein synthesis [<a href="#rid8">8</a>]. If sufficient nonprotein energy intake cannot be achieved, due to glucose or lipid intolerance, energy rather than protein will be rate-limiting for tissue anabolism and lower protein intakes should be given to avoid the acid load and ammonia/urea load that will result from catabolism of excess amino acids.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extremely low birth weight (ELBW) infants</strong> – For ELBW infants (&lt;1000 g), somewhat lower amino acid intakes (eg, approximately 2.5 to 3.0 g/kg/day) may be appropriate during the first week of life. This is suggested by a trial in 499 infants with birth weight &lt;1000 g who were randomized to receive a supplementary 1 g/kg/day of amino acid during the first five days of life or placebo in addition to their normal enteral and parenteral nutrition [<a href="#rid13">13</a>]. This resulted in average parenteral amino acid intake over the first five days of life of 3.4±0.6 g/kg/day in the supplemented group, compared with 2.6±0.6 g/kg/day in the standard PN group. At two years of age, there was no difference in the primary outcome (survival without neurodevelopmental impairment), but there were differences in secondary outcomes including a higher rate of moderate to severe neurodisability in children who had received the high-dose amino acids compared with those who received lower-dose amino acids (16.5 versus 8.6 percent; adjusted relative risk 1.95, 95% CI 1.09-3.48). There were no differences in mild neurodevelopmental impairment or in most other components of the Bayley III. The incidence of patent ductus arteriosus was more common in the higher-amino acid group.</p><p></p><p class="bulletIndent1">The approach outlined above is slightly more cautious for ELBW infants than that outlined in the 2018 European guidelines for parenteral amino acid intake, which do not distinguish between ELBW and VLBW infants and recommend a targeted amino acid intake of 2.5 to 3.5 g/kg/day by day 2 [<a href="#rid11">11</a>] and maximum intakes of 3.5 g/kg/day [<a href="#rid11">11,12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Larger infants</strong> – For larger infants (≥1500 g), lower parenteral protein intakes are appropriate. One recommendation is a maximum parenteral protein intake of 3 g/kg for 1500 to 2000 g and 2.5 g/kg for 2000 to 2500 g (compared with 3.5 g/kg for infants &lt;1500 g) [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of specific amino acids</strong> – Special "pediatric" amino acid solutions contain a higher concentration of essential amino acids and lower quantities of nonessential amino acids compared with adult formulations. The formulation is designed to produce plasma amino acid patterns that mimic those of healthy, breastfed neonates. Essential amino acids include isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine. In the premature infant, other amino acids may be conditionally essential because the premature infant has a limited ability to synthesize them.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="13196" href="/z/d/drug information/13196.html" rel="external">Cysteine</a> and glutamate are not included in a standard pediatric amino acid solution. Considerations are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cysteine</strong> – Many neonatal intensive care units add <a class="drug drug_pediatric" data-topicid="13196" href="/z/d/drug information/13196.html" rel="external">cysteine</a> to PN for preterm infants. A typical dose is 20 to 40 mg of cysteine for each gram of amino acid. Although the data are contradictory [<a href="#rid14">14,15</a>], addition of cysteine to PN appears to improve nitrogen retention [<a href="#rid16">16</a>]. However, addition of cysteine also reduces the pH of the PN solution and increases metabolic acidosis in preterm infants, therefore increasing the need for acetate supplementation to normalize the pH [<a href="#rid17">17</a>]. The lower pH of the PN solution does have some benefits as it increases the solubility of calcium and phosphate and reduces the risk of precipitation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glutamate</strong> – Because glutamate is a conditionally essential amino acid for preterm infants, it has been suggested that supplementation might improve growth or development. However, a few studies of glutamate supplementation of PN for preterm infants found no effects on neonatal growth, morbidity, or mortality [<a href="#rid18">18,19</a>]. One small study suggested that supplementation may increase brain white matter volume in later life [<a href="#rid20">20</a>].</p><p></p><p class="headingAnchor" id="H3612138741"><span class="h2">Lipids</span><span class="headingEndMark"> — </span>Lipids are an important component of PN for preterm infants. They are an important source of energy. They are also needed to prevent essential fatty acid deficiency, which can occur within the first week of life, and as early as the second day [<a href="#rid21">21</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiation</strong> – Lipids are typically initiated at 1 to 2 g/kg/day of intravenous lipid emulsion (ILE) [<a href="#rid22">22</a>]. ILE can be safely started on the first day of life [<a href="#rid23">23</a>]. Early (before day 5) introduction of lipids is not associated with any short-term differences in morbidity [<a href="#rid24">24</a>], but neither is it associated with improved growth or weight gain [<a href="#rid24">24</a>]. A minimum infusion of 0.25 g/kg/day is probably sufficient to prevent essential fatty acid deficiency in the short term [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">ILE should be infused continuously over 24 hours/day. In the past, it was common to infuse the lipids over 15 to 22 hours daily, but continuous infusion of the lipid is better tolerated [<a href="#rid26">26,27</a>]. Rapid infusion of ILE is associated with risk for a syndrome of clinical decompensation, especially in infants [<a href="#rid28">28-30</a>]. This risk is minimized by intermittent monitoring of triglycerides and gradual advancement to target rates, as described below. Care should be taken to avoid more rapid infusions, even for a few hours. Maximal infusion rates, which depend on ILE type, are described in the manufacturer's prescribing information [<a href="#rid31">31-33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent advancement</strong> – The dose of ILE should be advanced to 2 to 3 g/kg/day as tolerated, to ensure adequate caloric intake. Elevated serum triglyceride (TG) levels are relatively common in preterm infants, especially in the smallest and most immature infants, those receiving higher doses of intravenous lipids, or those with sepsis [<a href="#rid34">34</a>]. Therefore, we check TG once when the infusion reaches 2 g/kg/day lipids, and check again after any increase above this level, or when infants become septic. We adjust the ILE dose to maintain serum TG below approximately 200 or 250 mg/dL [<a href="#rid34">34,35</a>]. However, there is little clinical evidence that TG concentrations above this threshold are associated with morbidity or mortality [<a href="#rid35">35</a>]. For some infants who are chronically dependent on PN, it may be necessary to accept somewhat higher TG values (eg, up to 300 mg/dL). (See <a class="local">'Hyperlipidemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of ILE</strong> – The ILE most commonly used in the United States is a <a class="drug drug_pediatric" data-topicid="13296" href="/z/d/drug information/13296.html" rel="external">soybean oil-based lipid emulsion</a> with egg phospholipids  (<a class="graphic graphic_table graphicRef74733" href="/z/d/graphic/74733.html" rel="external">table 2</a>). It is usually given as a 20% solution (Intralipid 20). Intralipid is also available as a 10% solution, but this formulation has fallen out of favor as the 20% solution is better tolerated due to its lower phospholipid content [<a href="#rid36">36</a>]. The soybean oil is a good source of essential fatty acids (linoleic acid and linolenic acid) but also contains phytosterols, which may be implicated in the development of PN-associated liver disease (PNALD). (See <a class="local">'Liver toxicity'</a> below and  <a class="medical medical_review" href="/z/d/html/5948.html" rel="external">"Intestinal failure-associated liver disease in infants"</a>.)</p><p></p><p class="bulletIndent1">In an effort to reduce the risk of liver toxicity, alternative forms of ILE have been developed including a <a class="drug drug_pediatric" data-topicid="118810" href="/z/d/drug information/118810.html" rel="external">fish oil-based lipid emulsion</a> (Omegaven) or a combination of <a class="drug drug_pediatric" data-topicid="110860" href="/z/d/drug information/110860.html" rel="external">soybean, medium-chain triglyceride, olive, and fish oil lipid emulsion</a> (SMOFlipid). These are now approved for use in this age group in the United States and Europe. (See <a class="local">'Liver toxicity'</a> below.)</p><p></p><p class="headingAnchor" id="H281073105"><span class="h2">Calcium and phosphate</span><span class="headingEndMark"> — </span>Phosphorus and phosphate are often confused. Phosphorus, an element, is overwhelmingly found in biologic systems as phosphate ([PO<sub>4</sub>]<sup>3-</sup>). Phosphate is the form added to PN, the form that may precipitate with calcium, and the form measured in serum. One mole of phosphate contains 1 mole phosphorus, and 100 mg of phosphate contains approximately 32 mg of phosphorus. By convention, dietary requirements are usually expressed in terms of phosphorus. ILEs contain phospholipids, which provide a small but clinically insignificant amount of organic phosphate.</p><p>To optimize bone mineralization (especially in VLBW infants) and avoid hypophosphatemia, the PN for preterm infants should have relatively high concentrations of calcium and phosphate, as well as an optimal calcium:phosphate ratio. However, achievement of this goal is limited by PN admixture considerations, especially avoidance of calcium/phosphate precipitates.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Target intake</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Calcium and phosphorus needs</strong> – To maximize bone mineralization, high concentrations of calcium and phosphate are generally recommended in PN for preterm infants. Target intakes are 65 to 100 mg/kg/day of elemental calcium and 50 to 80 mg/kg/day of phosphorus  (<a class="graphic graphic_table graphicRef117237" href="/z/d/graphic/117237.html" rel="external">table 1</a>) [<a href="#rid3">3,37</a>] and can be achieved in most VLBW infants.</p><p></p><p class="bulletIndent2">Evidence supporting these targets comes from a study in which increasing calcium intake from 45 mg/kg/day to 75 mg/kg/day and increasing phosphorus from 26.5 mg/kg/day to 44 mg/kg/day improved bone strength (measured by ultrasound speed of sound) [<a href="#rid38">38</a>]. Similar changes in intake were also associated with improved calcium and phosphorus retention [<a href="#rid39">39</a>]. Further increases in calcium (approximately 88 mg/kg/day) and phosphorus (approximately 80 mg/kg/day) intakes lead to greater calcium and phosphorus balance, and improved bone mineralization compared with lower parenteral intakes (65 and 60 mg/kg/day, respectively) [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Calcium:phosphorus ratio</strong> – Bone mineralization is also affected by the ratio of calcium:phosphorus in PN. The optimal ratio is approximately 1.7:1 (mg/mg, or mass ratio), or 1.3:1 (molar ratio), as recommended by the American Society for Parenteral and Enteral Nutrition (ASPEN) [<a href="#rid37">37</a>]. Supportive data include a randomized trial, in which a ratio of 1.7:1 (mg/mg) was associated with improved calcium and phosphorus retention compared with ratios of 1.3:1 or 2:1 [<a href="#rid41">41</a>]. Other experts have recommended somewhat lower calcium:phosphorus ratios, ranging from 1.1:1 to 1.5:1 (mg/mg) [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1">Hypophosphatemia occurs in up to 60 percent of preterm infants receiving PN [<a href="#rid42">42-44</a>]. In many cases, this can be explained by low absolute intakes of phosphate (as little as 20 to 30 mg/kg/day phosphorus) [<a href="#rid42">42,43</a>], or by a high calcium:phosphate ratio (eg, 2:1 [calcium 100 mg/kg/day, phosphorus 50 mg/kg/day]) [<a href="#rid44">44</a>]. The phosphate requirement and optimal calcium:phosphorus ratio also may depend on the amino acid intake. This was suggested by one study, which found that hypophosphatemia and hypercalcemia were more likely if amino acids were initiated early without sufficient phosphorus (phosphate) intake [<a href="#rid45">45</a>]. These investigators proposed a formula to calculate the phosphorus requirement based on calcium and amino acid intake, but it is unclear if their findings are generalizable because the infants in this study had relatively low calcium and amino acid intakes.</p><p></p><p class="bulletIndent1">Similarly, hypercalcemia in preterm infants usually is caused by low absolute intakes of phosphate, a high calcium:phosphate ratio, or delayed introduction of phosphate-containing PN (eg, beginning parenteral phosphate after 72 hours of life) [<a href="#rid46">46</a>]. It is important that calcium not be given without phosphate or phosphate without calcium for more than a day or two, because this can quickly lead to hyper- or hypocalcemia, and also because bone mineralization requires concurrent availability of both calcium and phosphate. If calcium or phosphorus are administered alone, ionized calcium and serum phosphorus should be assessed each day. Other less common causes of hypercalcemia in neonates are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6125.html" rel="external">"Nephrocalcinosis in neonates", section on 'Hypercalcemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium and phosphate precipitation</strong> – One factor limiting the delivery of high amounts of calcium and phosphate is the risk of the formation of precipitates of bibasic calcium phosphate crystals that have been associated with pulmonary thromboemboli, which can be fatal [<a href="#rid47">47-49</a>]. The prediction of precipitation is complex. Precipitation becomes more likely as the amount of calcium and phosphate (and their product) increase.</p><p></p><p class="bulletIndent1">Factors that <strong>reduce</strong> the risk of precipitation include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lower pH [<a href="#rid50">50</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>The addition of <a class="drug drug_pediatric" data-topicid="13196" href="/z/d/drug information/13196.html" rel="external">cysteine</a> to PN (because this lowers pH) [<a href="#rid51">51</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Higher concentrations of amino acids [<a href="#rid52">52</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Use of the monobasic phosphate salt (which is more soluble than the bibasic salt) [<a href="#rid52">52,53</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Use of <a class="drug drug_pediatric" data-topicid="12956" href="/z/d/drug information/12956.html" rel="external">calcium gluconate</a> (which is less likely to precipitate than <a class="drug drug_pediatric" data-topicid="12651" href="/z/d/drug information/12651.html" rel="external">calcium chloride</a>) [<a href="#rid54">54</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Higher glucose concentration</p><p class="bulletIndent2"><span class="glyph">•</span>Prevention of excessive warming of the solution</p><p class="bulletIndent2"><span class="glyph">•</span>Using PN less than 24 hours after it was formulated</p><p></p><p class="bulletIndent1">Newer <strong>organic</strong> phosphate sources may effectively remove the risk of precipitation [<a href="#rid55">55,56</a>]. In these forms, phosphate is part of an organic molecule (glycerol-1-phosphate, glucose-1-phosphate, or fructose-1, 6-phosphate), rather than a phosphate salt. The phosphate in these organic sources is unable to interact with calcium, and is released in the cell when the parent compound is metabolized. These products are not available in the United States.</p><p></p><p class="headingAnchor" id="H2295706630"><span class="h2">Trace minerals</span><span class="headingEndMark"> — </span>A variety of trace minerals are routinely added to PN for preterm infants  (<a class="graphic graphic_table graphicRef117237" href="/z/d/graphic/117237.html" rel="external">table 1</a>). Many of these are probably not important if PN is a short-term bridge to full enteral nutrition. However, they become increasingly important the longer PN is continued.</p><p>Standard formulations of trace elements include zinc, copper, <a class="drug drug_pediatric" data-topicid="98778" href="/z/d/drug information/98778.html" rel="external">selenium</a>, <a class="drug drug_pediatric" data-topicid="140499" href="/z/d/drug information/140499.html" rel="external">manganese</a> and <a class="drug drug_pediatric" data-topicid="140646" href="/z/d/drug information/140646.html" rel="external">chromium</a>. These are typically added to the PN within the first few days of life, while the PN is advanced to meet full nutritional needs. Iodine is not included in most trace element preparations and is rarely added to PN. If PN is continued for several months, iodine deficiency may develop, with associated hypothyroidism [<a href="#rid57">57</a>]. If topical iodine is used to disinfect the skin, premature infants may receive sufficient iodine or even excess iodine exposure (see  <a class="medical medical_review" href="/z/d/html/5840.html" rel="external">"Thyroid physiology and screening in preterm infants"</a> and  <a class="medical medical_review" href="/z/d/html/5838.html" rel="external">"Acquired hypothyroidism in childhood and adolescence", section on 'Iodine deficiency'</a>). Molybdenum is also not included in most trace element preparations, and routine supplementation in PN is not recommended by ASPEN [<a href="#rid58">58,59</a>].</p><p>Both zinc and copper deficiency are well described in preterm infants on prolonged PN containing suboptimal amounts of copper or zinc, although it typically takes many months for symptoms to develop [<a href="#rid60">60</a>]. Larger amounts of zinc may be needed in infants with intestinal losses, due to diarrhea or short bowel syndrome (see  <a class="medical medical_review" href="/z/d/html/5354.html" rel="external">"Zinc deficiency and supplementation in children", section on 'Underlying medical conditions'</a>). Symptomatic zinc deficiency has been reported in infants with abnormal losses or reduced absorption, or those receiving low amounts of parenteral zinc (40 mcg/kg/day) [<a href="#rid61">61</a>]. Similarly, copper deficiency has been reported in preterm infants with short bowel syndrome receiving 10 to 20 mcg/kg/day of copper in PN, likely due to a combination of low copper intake in PN and increased enteral losses [<a href="#rid62">62</a>].</p><p>For infants with cholestatic liver disease, the dose of copper and <a class="drug drug_pediatric" data-topicid="140499" href="/z/d/drug information/140499.html" rel="external">manganese</a> should be reduced because these elements are excreted in the bile [<a href="#rid63">63</a>]. In these patients, we reduce the frequency of copper and manganese administration to twice a week. Of note, other components of PN (particularly <a class="drug drug_pediatric" data-topicid="12982" href="/z/d/drug information/12982.html" rel="external">magnesium sulfate</a> and <a class="drug drug_pediatric" data-topicid="12956" href="/z/d/drug information/12956.html" rel="external">calcium gluconate</a>) may contain significant amounts of manganese as contaminants [<a href="#rid64">64</a>].</p><p>For infants with impaired renal function, <a class="drug drug_pediatric" data-topicid="98778" href="/z/d/drug information/98778.html" rel="external">selenium</a> should be eliminated or reduced because it is excreted renally.</p><p><a class="drug drug_pediatric" data-topicid="140646" href="/z/d/drug information/140646.html" rel="external">Chromium</a> and <a class="drug drug_pediatric" data-topicid="98778" href="/z/d/drug information/98778.html" rel="external">selenium</a> are included in most formulations of trace elements. Limited evidence suggests that addition of chromium to PN may improve glucose tolerance [<a href="#rid65">65</a>], and that selenium supplementation of PN may reduce the rates of sepsis [<a href="#rid63">63</a>] or respiratory disease [<a href="#rid66">66</a>].</p><p>Iron is not routinely added to PN for preterm infants. There is little evidence of benefit for parenteral iron administration during the first few months of life in preterm infants [<a href="#rid67">67</a>]. As an example, <a class="drug drug_pediatric" data-topicid="13057" href="/z/d/drug information/13057.html" rel="external">iron dextran</a> (0.25 mg/kg/day for the first five weeks of life) had no significant effect on hemoglobin concentration, growth, or the risk of sepsis [<a href="#rid68">68</a>]. Neonates who are treated with erythropoiesis stimulating agents may require additional iron supplementation, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4962.html" rel="external">"Anemia of prematurity (AOP)", section on 'Additional iron supplementation'</a>.)</p><p class="headingAnchor" id="H1760252691"><span class="h2">Vitamins</span><span class="headingEndMark"> — </span>Premature infants need higher amounts of some vitamins than do term infants because of increased requirements for growth and/or greater losses. However, there are no commercially available vitamin formulations that are specifically designed to meet the needs of premature infants. Pediatric vitamin formulations generally meet or exceed the estimated vitamin needs for premature infants, as outlined in the table  (<a class="graphic graphic_table graphicRef76606" href="/z/d/graphic/76606.html" rel="external">table 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin A</strong> – <a class="drug drug_pediatric" data-topicid="12883" href="/z/d/drug information/12883.html" rel="external">Vitamin A</a> is a fat-soluble vitamin with multiple functions including effects on vision (corneal and conjunctival development, and phototransduction), immunocompetency, and cell differentiation. In premature infants, vitamin A is necessary for normal lung growth and maintaining the integrity of respiratory tract epithelial cells.</p><p></p><p class="bulletIndent1">VLBW infants generally have lower stores of <a class="drug drug_pediatric" data-topicid="12883" href="/z/d/drug information/12883.html" rel="external">vitamin A</a> than are considered optimal: one-third have hepatic stores &lt;20 grams vitamin A/gram liver (g/g), indicative of deficiency, and three-fourths have stores of &lt;40 g/g [<a href="#rid69">69</a>]. However, vitamin A is the most difficult vitamin to provide parenterally in sufficient quantities to VLBW infants without administering excessive quantities of other vitamins because of its loss through photodegradation and binding to the PN-containing bag and tubing [<a href="#rid70">70</a>]. Mixing the vitamin with intravenous lipid emulsion or use of retinyl esters helps to achieve greater plasma concentrations of vitamin A [<a href="#rid71">71,72</a>].</p><p></p><p class="bulletIndent1">Clinical trials suggest that treatment of VLBW infants with supplemental <a class="drug drug_pediatric" data-topicid="12883" href="/z/d/drug information/12883.html" rel="external">vitamin A</a> is associated with a modest benefit in reducing the risk of chronic lung disease [<a href="#rid70">70</a>]. However, the clinical relevance of these studies is unclear because they used a combination of parenteral and enteral vitamin A and were carried out in populations with high rates of chronic lung disease. (See  <a class="medical medical_review" href="/z/d/html/4992.html" rel="external">"Bronchopulmonary dysplasia (BPD): Prevention", section on 'Vitamin A'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitamin E</strong> – <a class="drug drug_pediatric" data-topicid="12884" href="/z/d/drug information/12884.html" rel="external">Vitamin E</a> is a free-radical scavenger (antioxidant) that protects polyunsaturated fatty acids, a major structural component of the cell membranes, from peroxidation. Data from older randomized trials in premature infants suggested that vitamin E reduced the risk of bronchopulmonary dysplasia and retinopathy of prematurity. However, subsequent studies have demonstrated little or no risk reduction with the use of pharmacologic doses of vitamin E [<a href="#rid73">73-78</a>].</p><p></p><p class="bulletIndent1">Some studies suggest that administration of <a class="drug drug_pediatric" data-topicid="12884" href="/z/d/drug information/12884.html" rel="external">vitamin E</a> within 12 hours of birth reduced the incidence and severity of intraventricular hemorrhage (IVH) [<a href="#rid79">79,80</a>]. These studies are several decades old and have not been replicated. The suggested target plasma level of vitamin E for reducing IVH was &gt;1 mg/dL by 24 hours of life and &gt;2 mg/dL at three days of age [<a href="#rid81">81</a>]. These concentrations can be achieved with administration of the recommended dose of the available multivitamin formulations, which provide a vitamin E dose of 2.8 mg/kg/day, starting soon after birth  (<a class="graphic graphic_table graphicRef76606" href="/z/d/graphic/76606.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Water-soluble vitamins</strong> – The available multivitamin formulations generally provide more water-soluble vitamins than are needed by premature infants. The usual dosing of pediatric multivitamin formulations achieves adequate levels of thiamine (vitamin B1), riboflavin (vitamin B2), folate, and vitamin B12 [<a href="#rid82">82</a>]. There are several reports of elevated levels of plasma ascorbic acid (vitamin C), and riboflavin (vitamin B2) in premature infants receiving PN [<a href="#rid83">83,84</a>], but it is unclear whether or not these increased concentrations have any adverse effects.</p><p></p><p class="headingAnchor" id="H741762500"><span class="h2">Other parenteral nutrition components</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>L-carnitine</strong> – L-carnitine supplements are typically added only for prolonged courses of PN (eg, more than approximately three weeks). L-carnitine is important for transport of fatty acids into the mitochondria. Early studies suggested that carnitine insufficiency can develop in preterm infants on PN, leading to impaired fatty acid oxidation and ketogenesis, and that these effects were reversible with <a class="drug drug_pediatric" data-topicid="13119" href="/z/d/drug information/13119.html" rel="external">carnitine supplementation</a> [<a href="#rid85">85,86</a>]. However, randomized controlled trials and meta-analysis have found no effect of carnitine supplementation on apnea, duration of ventilatory support and hospital length of stay [<a href="#rid87">87</a>], triglyceride (TG) or free fatty acid levels [<a href="#rid88">88</a>], or weight gain [<a href="#rid89">89</a>], although small differences in ketogenesis have been reported [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heparin</strong> – We suggest adding heparin to most neonatal PN solutions, especially those running via a central venous catheter. The addition of heparin to neonatal PN may reduce the incidence of central venous catheter obstruction and/or catheter-related sepsis, based on limited evidence [<a href="#rid90">90-93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insulin</strong> – Addition of insulin to PN is not recommended for most premature infants, because the risk of hypoglycemia outweighs the potential benefits of insulin on growth, which are transient [<a href="#rid2">2</a>]. (See <a class="local">'Hyperglycemia'</a> below.)</p><p></p><p class="bulletIndent1">Evidence against routine use of insulin infusions in preterm infants includes a study in which early administration of insulin (0.05 units/kg/hour) was associated with higher rates of hypoglycemia and no overall improvement in growth by 28 days of age, despite lower rates of hyperglycemia and less weight loss in the first week of life [<a href="#rid94">94</a>]. These findings overshadow those in an earlier pilot study, which reported reduced rates of hyperglycemia, higher insulin-like growth factor 1 levels, and improved short-term linear growth rates [<a href="#rid95">95</a>]. (See  <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">"Neonatal hyperglycemia"</a>.)</p><p></p><p class="headingAnchor" id="H2447562729"><span class="h1">ADMINISTRATION</span><span class="headingEndMark"> — </span>PN can be administered either through a central venous catheter (eg, peripherally-inserted central catheter or implanted port), or via a peripheral venous catheter or a "long line" (a catheter that is deeply inserted but not central).</p><p>Central catheters are generally preferable because they can be used with PN solutions of higher osmolarity compared with PN solutions for peripheral administration (which generally should be limited to an osmolarity of less than 900 mOsm/L) [<a href="#rid37">37</a>]. The use of a central catheter is also associated with higher nutrient intake and reduced need for line replacement, without any increase in infection risk [<a href="#rid96">96</a>].</p><p>The tubing used to administer PN should include an inline filter to exclude particulate matter such as precipitates. The filter is located as close to the infant as possible [<a href="#rid97">97</a>].</p><p class="headingAnchor" id="H2006319504"><span class="h1">ADVERSE EFFECTS OF PARENTERAL NUTRITION</span><span class="headingEndMark"> — </span>Adverse effects of PN can result from:</p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate intake (or unbalanced intake) of nutrients</p><p class="bulletIndent1"><span class="glyph">●</span>Intolerance of PN (hyperglycemia, hyperlipidemia)</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of toxic products or contaminants in PN</p><p class="bulletIndent1"><span class="glyph">●</span>Chemical modification of PN (eg, photo-oxidation)</p><p class="bulletIndent1"><span class="glyph">●</span>Complications of the central venous lines that are required to give high quality, concentrated PN</p><p></p><p>Certain adverse effects have more complex pathogenesis. In particular, the toxic effects of PN on the liver (known as PN-associated liver disease [PNALD], or intestinal failure-associated liver disease [IFALD]), are probably due to a combination of immature liver function, toxicity from certain components of parenterally administered lipid formulations, exacerbated by bacterial translocation or sepsis. (See <a class="local">'Liver toxicity'</a> below.)</p><p class="headingAnchor" id="H800110255"><span class="h2">Hyperglycemia</span><span class="headingEndMark"> — </span>Hyperglycemia occurs during PN administration in more than one-half of preterm infants, and is especially common in those with extremely low birth weight or extreme prematurity [<a href="#rid98">98</a>]. Premature infants are prone to hyperglycemia due to a combination of factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired sensing of hyperglycemia</p><p class="bulletIndent1"><span class="glyph">●</span>Reduced insulin production and secretion</p><p class="bulletIndent1"><span class="glyph">●</span>End organ insulin resistance</p><p class="bulletIndent1"><span class="glyph">●</span>The glycemic effects of stress or sepsis, mediated by counterregulatory hormones such as catecholamines and glucocorticoids</p><p class="bulletIndent1"><span class="glyph">●</span>Failure of down-regulation of gluconeogenesis in the face of elevated blood glucose</p><p></p><p>Hyperglycemia in preterm infants is associated with adverse outcomes, including death and severe intraventricular hemorrhage (IVH) [<a href="#rid98">98,99</a>]. Treatment of hyperglycemia may decrease mortality in animal models [<a href="#rid100">100</a>], but there is little evidence of efficacy in preterm infants.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood glucose target</strong> – For preterm infants, common practice is to try to maintain blood glucose above 47 mg/dL; there are no obvious reasons why blood glucose should be lower in preterm infants than in term infants. The American Society for Parenteral and Enteral Nutrition (ASPEN) recommends a minimum glucose threshold of &gt;40 mg/dL [<a href="#rid101">101</a>]. However, the evidence for this target range is weak since no specific blood glucose threshold has been identified that is associated with worse clinical outcomes, or at which treatment of hyperglycemia improves outcomes. As an example, a randomized study of tight glycemic control (achieved with an insulin infusion of 0.05 units/kg/hour and target blood glucose 72 to 106) failed to demonstrate any change in mortality or morbidity compared with standard practice [<a href="#rid102">102</a>]. Although the tightly controlled group had greater weight and head circumference gains, they had lower length gain and increased incidence of hypoglycemia [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Strategies</strong> – Strategies for maintaining blood glucose in the target range include the use of parenteral lipids and limiting glucose infusion rates, as well as insulin administration for severe hyperglycemia [<a href="#rid101">101</a>]. (See <a class="local">'Other parenteral nutrition components'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong> – Our usual practice is to carefully assess and treat low blood glucose levels (&lt;45 to 50 mg/dL), but to be tolerant of moderately elevated glucose levels (eg, blood glucose 250 to 350 mg/dL).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We begin parenteral protein and lipids, and enteral feeds, as soon as possible after birth.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If blood glucose levels exceed 250 mg/dL, we reduce glucose infusion rates in the short term, but generally not below a glucose infusion rate of 5 to 8 mg/kg/minute (or 7.2 to 11.5 g/kg/day of dextrose), which is the basal glucose requirement for preterm infants.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If blood glucose concentrations are consistently above 250 to 400 mg/dL despite reducing the glucose infusion rate, we consider treatment with insulin.</p><p></p><p class="bulletIndent2">However, our own anecdotal experience is that the need for insulin treatment is not generally needed if parenteral protein and lipid are started early, and if enteral feeds are started early and advanced appropriately (ie, quite rapidly).</p><p></p><p class="bulletIndent2">If insulin is required, the initial dose is typically 0.05 to 0.1 units/kg/hour, adjusted to target a blood glucose of 150 to 250 mg/dL. However, we use insulin only in selected cases with persistent severe hyperglycemia. This is because there is no clear evidence that short- or medium-term exposure to moderate hyperglycemia is detrimental in preterm babies, and the use of insulin is associated with greater risk of hypoglycemia, which is clearly detrimental to preterm infants. Hypoglycemia is usually accompanied by increases in alternate energy substrates (free fatty acids and ketones); however, hypoglycemia due to insulin therapy is associated with low free fatty acids and ketone levels, which may make it particularly damaging. (See <a class="local">'Other parenteral nutrition components'</a> above.)</p><p></p><p>(See  <a class="medical medical_review" href="/z/d/html/4981.html" rel="external">"Neonatal hyperglycemia", section on 'Management'</a>.)</p><p class="headingAnchor" id="H3473311696"><span class="h2">Hyperlipidemia</span><span class="headingEndMark"> — </span>Target triglyceride (TG) concentrations for infants receiving intravenous lipid emulsion (ILE) are typically &lt;250 mg/dL, if possible [<a href="#rid34">34,35</a>]. Elevations above this threshold are uncommon unless lipid infusion rates are &gt;2 g/kg/day, or in very preterm or low birth weight infants, or if sepsis develops. TG levels up to 250 or 300 mg/dL may be acceptable in some cases. (See <a class="local">'Lipids'</a> above.)</p><p>Limited data suggest that ILE may reduce bacterial clearance in septic infants [<a href="#rid103">103</a>] and might be associated with an increased risk of chronic lung disease [<a href="#rid104">104</a>]. Data are conflicting as to whether ILE displaces bilirubin from albumin [<a href="#rid22">22,104</a>]. If so, excessive concentrations of ILE might increase the adverse effects of hyperbilirubinemia. The long-term effects of ILEs are unclear. One study suggested that individuals who received ILE during infancy had increased aortic stiffness and decreased cardiac function in young adults compared with controls with similar perinatal characteristics [<a href="#rid105">105</a>], but this remains to be confirmed.</p><p class="headingAnchor" id="H1921439455"><span class="h2">Liver toxicity</span><span class="headingEndMark"> — </span>The ILE most commonly used in the United States is a soy-based emulsion (Intralipid). However, alternative ILEs are increasingly used and are now approved for this age group in the United States and Europe [<a href="#rid106">106-108</a>]. This is largely driven by concerns about the phytosterol content of soybean oil and its potential relationship to the development of IFALD, also known as PNALD. (See  <a class="medical medical_review" href="/z/d/html/5948.html" rel="external">"Intestinal failure-associated liver disease in infants"</a>.)</p><p>In light of these concerns, it seems prudent to limit exposure to soy-based ILE as much as possible and to use alternative forms of ILE in selected patients  (<a class="graphic graphic_table graphicRef74733" href="/z/d/graphic/74733.html" rel="external">table 2</a>). To do this, our personal practice is:</p><p class="bulletIndent1"><span class="glyph">●</span>Limit Intralipid infusions to 2 to 3 g/kg/day, when possible, as long as this is compatible with the provision of adequate parenteral calories.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduce Intralipid to 1 g/kg/day in infants who have developed IFALD, or are at very high risk of doing so, such as those who have had extensive gastrointestinal resections and risk of short bowel syndrome. This strategy is appropriate only if it is compatible with the provision of adequate parenteral calories.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use alternative lipids with lower phytosterol levels (eg, a mixed <a class="drug drug_pediatric" data-topicid="110860" href="/z/d/drug information/110860.html" rel="external">soybean, medium-chain triglyceride, olive, and fish oil lipid emulsion</a> [SMOF]) for selected infants at high risk of developing IFALD, such as those with severe short bowel syndrome who are likely to require long-term PN support.</p><p></p><p class="bulletIndent1">Clinical evidence regarding SMOF ILE for prevention of IFALD is limited, and practice varies regarding selection of infants for this form of ILE. A reasonable approach would be to use it in infants at high risk of IFALD whose direct bilirubin is &gt;2 mg/dL. SMOF ILE is available in Europe and the United States. (See  <a class="medical medical_review" href="/z/d/html/5948.html" rel="external">"Intestinal failure-associated liver disease in infants", section on 'Composite lipid emulsions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use a <a class="drug drug_pediatric" data-topicid="118810" href="/z/d/drug information/118810.html" rel="external">fish oil-based lipid emulsion</a> (eg, Omegaven) for infants with established IFALD (direct bilirubin &gt;2 mg/dL for more than two to four weeks) who are likely to remain on PN for at least another four weeks. (See  <a class="medical medical_review" href="/z/d/html/5948.html" rel="external">"Intestinal failure-associated liver disease in infants", section on 'Fish oil-based lipid emulsions'</a>.)</p><p></p><p class="headingAnchor" id="H439416539"><span class="h2">Aluminum toxicity</span><span class="headingEndMark"> — </span>Aluminum is a widespread contaminant of PN components, especially <a class="drug drug_pediatric" data-topicid="12956" href="/z/d/drug information/12956.html" rel="external">calcium gluconate</a>, phosphate salts, and vitamin C [<a href="#rid109">109</a>]. Toxicity is most likely due to deposition in bone and brain in preterm infants [<a href="#rid109">109</a>]; limited evidence suggests that preterm infants who receive higher intakes of parenteral aluminum may have worse neurodevelopment as toddlers and lower bone mineralization as adolescents [<a href="#rid110">110,111</a>]. Although reduction in aluminum load is clearly desirable, it is difficult to achieve using available PN products. The FDA recommends that PN contain less than 25 mcg/L of aluminum, but this goal probably is infrequently achieved in clinical practice [<a href="#rid109">109,112</a>]. (See  <a class="medical medical_review" href="/z/d/html/5948.html" rel="external">"Intestinal failure-associated liver disease in infants", section on 'Pathogenesis'</a>.)</p><p class="headingAnchor" id="H2280140573"><span class="h2">Calcium/phosphate precipitates</span><span class="headingEndMark"> — </span>Precipitates of bibasic calcium phosphate crystals occasionally develop in PN and have been associated with pulmonary thromboemboli, which can be fatal, or interstitial pneumonitis [<a href="#rid47">47-49</a>]. This can be prevented by careful management of the PN admixture, including limits on concentrations of calcium, phosphate, and their product. (See <a class="local">'Calcium and phosphate'</a> above.)</p><p class="headingAnchor" id="H3260312304"><span class="h1">PRESCRIBING PARENTERAL NUTRITION AND ADJUSTING FOR FEEDS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prescribing approaches</strong> – More than 750,000 prescriptions for neonatal PN are written in the United States each year annually, and they are an important source of medical errors [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent1">One approach to reducing these errors has been to use a limited number of standardized PN solutions for infants rather than totally individualized solutions. The advantage of this approach was demonstrated in a study from Australia that used three main PN solutions (a starter solution, a preterm infant solution, and a term infant solution) with two option variants (higher sodium or lower glucose for preterm infants) [<a href="#rid114">114</a>]. Use of these standard solutions resulted in suboptimal protein and energy intakes during the first few days of life, but adequate protein and weight gain thereafter [<a href="#rid115">115</a>]. Similarly, another study reported that use of standard solutions was associated with modest weight loss in the first week of life [<a href="#rid116">116</a>]. The relative success of standard solutions may in part depend on who is doing the individualized prescribing. The optimal approach is probably individualized PN prescription by a pharmacist or other PN expert, where available, rather than the use of standardized solutions [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent1">An alternative approach is the use of computer-supported prescribing, which may reduce the time taken to prescribe PN and reduce errors, while also improving intake and growth [<a href="#rid118">118</a>]. However, the benefits may be modest. Clinical studies of this approach reported that computer-supported prescribing increased the number of babies receiving targeted nutritional intake from 5 to 25 percent [<a href="#rid119">119</a>], or reduced the time taken to achieve targeted nutritional intakes from 8.7 to 5.9 days [<a href="#rid120">120</a>].</p><p></p><p class="bulletIndent1">Another issue is whether PN should be prescribed as unit/kg/day (ie, g, mg or mEq/kg/day, depending on the component), or as a concentration and volume (infusion rate). Considerations are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Units/kg/day prescribing</strong> – The American Society for Parenteral and Enteral Nutrition (ASPEN) strongly supports this approach to prescribing PN [<a href="#rid121">121</a>]. This ensures optimal nutrient intakes when performed by an expert. The main disadvantage approach is that it requires frequent calculations and reformulation of PN because the relative contribution of enteral feeds and PN changes daily, or more often. As feeds increase, two adjustments are needed: one to reduce the prescribed parenteral intake as the enteral intake increases, and one to adjust for intolerance (or glucose or lipids) or to adjust electrolytes, calcium, and phosphate in response to biochemical monitoring  (<a class="graphic graphic_table graphicRef117239" href="/z/d/graphic/117239.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Concentration/volume prescribing</strong> – We prefer to this method because we find it to be simpler, more efficient, and less prone to error. This approach uses a "typical" PN solution  (<a class="graphic graphic_table graphicRef117238" href="/z/d/graphic/117238.html" rel="external">table 5</a>), which is designed to meet the nutritional needs of the infant if given at a rate of 130 mL/kg/day of PN, with 10 mL/kg/day of 20 percent Intralipid. Once an infant can tolerate trophic feeds (20 mL/kg/day), with full PN (130 mL/kg/day and Intralipid at 10 mL/kg/day), it is easy to gradually transition to enteral feeds by exchanging PN for enteral nutrition, mL for mL, until the target for full feeds is reached (160 mL/kg/day of fortified human milk or preterm formula). It is still necessary to adjust electrolytes, calcium, and phosphate in response to biochemical monitoring, but the concentration of nutrients remains the same, and only the PN rate is modified as enteral feeds advance. (See  <a class="medical medical_review" href="/z/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjusting for advances in enteral feeds</strong> – Regardless of the method used for PN prescribing, enteral nutrition should be steadily advanced to the target volume of 150 to 170 mL/kg/day of fortified human milk or preterm formula, as tolerated by the infant. More rapid advancement of feeds (30 mL/kg/day) seems to be as well tolerated and as safe as slower advancement (15 to 20 mL/kg/d) and can shorten the time to reach full feeds to within one to two weeks. (See  <a class="medical medical_review" href="/z/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant", section on 'Infants requiring tube feeding'</a>.)</p><p></p><p class="headingAnchor" id="H3575846843"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>There is little robust evidence to guide the frequency of biochemical monitoring, but our typical practice is:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood glucose</strong> – Checked at least twice daily while on intravenous fluids and more frequently if needed to maintain blood glucose in the target range.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Electrolytes, blood urea nitrogen, creatinine</strong> – Initially check every one to two days; later, two to three times a week. Very low birth weight (VLBW) infants may require more frequent measurements to guide fluid management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Calcium, phosphate, alkaline phosphatase</strong> – Check after approximately one week of PN, then every second week, or more frequently if there are concerns about the overall adequacy of calcium and phosphate intake. We use the reference range for preterm infants provided by the reporting laboratory and do not correct for hypoalbuminemia. (See <a class="local">'Calcium and phosphate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ionized calcium</strong> – Check after 12 to 24 hours, and as required.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Triglycerides</strong> – A reasonable approach is to measure triglycerides (TG) once on 2 g/kg/day lipids, and after any increase above this level, or if the infant becomes septic. Common practice is to try to keep TG below approximately 200 to 250 mg/dL. (See <a class="local">'Lipids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver tests</strong> – Check alanine aminotransferase, aspartate aminotransferase, and cholestasis markers (total and direct bilirubin, gamma-glutamyl transferase) after approximately one week of PN, then every one to two weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Albumin, prealbumin</strong> – These are not measured routinely; they are typically only measured in response to concerns about suboptimal growth.</p><p></p><p class="headingAnchor" id="H2994663161"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/143917.html" rel="external">"Society guideline links: Nutrition support (parenteral and enteral nutrition) for neonates including preterm infants"</a>.)</p><p class="headingAnchor" id="H3382417403"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initiation of parenteral nutrition (PN)</strong> – For preterm infants, PN should be started as soon as possible after birth, ideally on the first day of life. The initial targets for nutrient composition are designed to prevent catabolism and hypocalcemia. The initial prescription should include  (<a class="graphic graphic_table graphicRef117237" href="/z/d/graphic/117237.html" rel="external">table 1</a>) (see <a class="local">'Parenteral nutritional requirements'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sufficient amino acid and energy to prevent catabolism (minimum protein 1.5 g/kg/day and energy 30 to 40 kcal/kg/day)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sufficient calcium to prevent hypocalcemia (at least 25 mg/kg/day)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Intravenous lipid emulsion (ILE), starting on the first or second day of life, to prevent essential fatty acid deficiency and to provide additional energy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent PN advancement</strong> – Nutrient composition in the PN is quickly advanced over the first 24 to 48 hours of life to provide full nutrition for optimal weight gain, protein deposition, and bone mineralization (full PN)  (<a class="graphic graphic_table graphicRef117237" href="/z/d/graphic/117237.html" rel="external">table 1</a>). Adjustments include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increase the amino acid intake and energy content to support growth; optimal targets depend on birth weight. (See <a class="local">'Amino acids'</a> above and <a class="local">'Energy requirements'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Advance the ILE to approximately 2 to 3 g/kg/day, while titrating the infusion to avoid hyperlipidemia and maintain appropriate nonprotein energy intakes. (See <a class="local">'Lipids'</a> above and <a class="local">'Hyperlipidemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Add phosphate, and advance the calcium concentration. For optimal bone mineralization, PN for preterm infants should have relatively high concentrations of calcium and phosphate, as well as a calcium:phosphate ratio of approximately 1.7:1. However, achievement of this goal is limited by PN admixture considerations, especially avoidance of calcium/phosphate precipitates, which can cause pulmonary emboli. (See <a class="local">'Calcium and phosphate'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Titrate the glucose infusion as needed to keep the whole blood glucose in the target range. If this prevents meeting caloric goals for greater than two to three days, insulin infusion should be considered. (See <a class="local">'Hyperglycemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Feeding advancement</strong> – Enteral nutrition (ideally of human milk) should be started on the first day of life at low volume (trophic feeds, at 20 mL/kg/day), then gradually advanced, while PN is decreased. The target for full feeds is 160 mL/kg/day of fortified human milk or preterm formula. (See <a class="local">'Prescribing parenteral nutrition and adjusting for feeds'</a> above and  <a class="medical medical_review" href="/z/d/html/5014.html" rel="external">"Approach to enteral nutrition in the premature infant", section on 'Infants requiring tube feeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory monitoring</strong> – Laboratory monitoring is required to adjust the contents of PN to avoid excesses or deficiencies of any given nutrient and to monitor for PN-associated complications. (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects of PN include hyperglycemia, hyperlipidemia, line infection, and sepsis. Prolonged use of soy-based ILE in premature infants is associated with development of cholestatic liver disease. For infants who develop liver disease, strategies include limiting total intake of intravenous lipids and use of alternative forms of ILE. (See <a class="local">'Adverse effects of parenteral nutrition'</a> above and <a class="local">'Liver toxicity'</a> above and <a class="local">'Lipids'</a> above.)</p><p></p><p class="headingAnchor" id="H1396394895"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Richard J Schanler, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wilmore DW, Dudrick SJ. Growth and development of an infant receiving all nutrients exclusively by vein. JAMA 1968; 203:860.</a></li><li><a class="nounderline abstract_t">Robinson DT, Calkins KL, Chen Y, et al. Guidelines for parenteral nutrition in preterm infants: The American Society for Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr 2023; 47:830.</a></li><li class="breakAll">Nutritional Care of Preterm Infants: Scientific Basis and Practical Guidelines, Koletzko B, Poindexter B, Uaay R (Eds), Karger, 2014.</li><li><a class="nounderline abstract_t">Salas-Salvadó J, Molina J, Figueras J, et al. Effect of the quality of infused energy on substrate utilization in the newborn receiving total parenteral nutrition. Pediatr Res 1993; 33:112.</a></li><li><a class="nounderline abstract_t">Bresson JL, Bader B, Rocchiccioli F, et al. Protein-metabolism kinetics and energy-substrate utilization in infants fed parenteral solutions with different glucose-fat ratios. Am J Clin Nutr 1991; 54:370.</a></li><li><a class="nounderline abstract_t">Piedboeuf B, Chessex P, Hazan J, et al. Total parenteral nutrition in the newborn infant: energy substrates and respiratory gas exchange. J Pediatr 1991; 118:97.</a></li><li><a class="nounderline abstract_t">Moyses HE, Johnson MJ, Leaf AA, Cornelius VR. Early parenteral nutrition and growth outcomes in preterm infants: a systematic review and meta-analysis. Am J Clin Nutr 2013; 97:816.</a></li><li class="breakAll">van Goudoever JB, Vlaardingerbroek H, van den Akker CH, et al. Amino acids and proteins. In: Nutritional Care of Preterm Infants: Scientific Basis and Practical Guidelines, Koletzko B, Poindexter B, Uaay R (Eds), Karger, 2014. p.49.</li><li><a class="nounderline abstract_t">Blanco CL, Falck A, Green BK, et al. Metabolic responses to early and high protein supplementation in a randomized trial evaluating the prevention of hyperkalemia in extremely low birth weight infants. J Pediatr 2008; 153:535.</a></li><li><a class="nounderline abstract_t">Burattini I, Bellagamba MP, Spagnoli C, et al. Targeting 2.5 versus 4 g/kg/day of amino acids for extremely low birth weight infants: a randomized clinical trial. J Pediatr 2013; 163:1278.</a></li><li><a class="nounderline abstract_t">van Goudoever JB, Carnielli V, Darmaun D, et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Amino acids. Clin Nutr 2018; 37:2315.</a></li><li><a class="nounderline abstract_t">Koletzko B, Wieczorek S, Cheah FC, et al. Recommended Nutrient Intake Levels for Preterm Infants. World Rev Nutr Diet 2021; 122:191.</a></li><li><a class="nounderline abstract_t">Bloomfield FH, Jiang Y, Harding JE, et al. Early Amino Acids in Extremely Preterm Infants and Neurodisability at 2 Years. N Engl J Med 2022; 387:1661.</a></li><li><a class="nounderline abstract_t">Malloy MH, Rassin DK, Richardson CJ. Total parenteral nutrition in sick preterm infants: effects of cysteine supplementation with nitrogen intakes of 240 and 400 mg/kg/day. J Pediatr Gastroenterol Nutr 1984; 3:239.</a></li><li><a class="nounderline abstract_t">Van Goudoever JB, Sulkers EJ, Timmerman M, et al. Amino acid solutions for premature neonates during the first week of life: the role of N-acetyl-L-cysteine and N-acetyl-L-tyrosine. JPEN J Parenter Enteral Nutr 1994; 18:404.</a></li><li><a class="nounderline abstract_t">Soghier LM, Brion LP. Cysteine, cystine or N-acetylcysteine supplementation in parenterally fed neonates. Cochrane Database Syst Rev 2006; :CD004869.</a></li><li><a class="nounderline abstract_t">Laine L, Shulman RJ, Pitre D, et al. Cysteine usage increases the need for acetate in neonates who receive total parenteral nutrition. Am J Clin Nutr 1991; 54:565.</a></li><li><a class="nounderline abstract_t">Poindexter BB, Ehrenkranz RA, Stoll BJ, et al. Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants. Pediatrics 2004; 113:1209.</a></li><li><a class="nounderline abstract_t">Moe-Byrne T, Brown JV, McGuire W. Glutamine supplementation to prevent morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2016; 4:CD001457.</a></li><li><a class="nounderline abstract_t">de Kieviet JF, Oosterlaan J, Vermeulen RJ, et al. Effects of glutamine on brain development in very preterm children at school age. Pediatrics 2012; 130:e1121.</a></li><li><a class="nounderline abstract_t">Friedman Z, Danon A, Stahlman MT, Oates JA. Rapid onset of essential fatty acid deficiency in the newborn. Pediatrics 1976; 58:640.</a></li><li><a class="nounderline abstract_t">Gutcher GR, Farrell PM. Intravenous infusion of lipid for the prevention of essential fatty acid deficiency in premature infants. Am J Clin Nutr 1991; 54:1024.</a></li><li><a class="nounderline abstract_t">Gilbertson N, Kovar IZ, Cox DJ, et al. Introduction of intravenous lipid administration on the first day of life in the very low birth weight neonate. J Pediatr 1991; 119:615.</a></li><li><a class="nounderline abstract_t">Simmer K, Rao SC. Early introduction of lipids to parenterally-fed preterm infants. Cochrane Database Syst Rev 2005; :CD005256.</a></li><li><a class="nounderline abstract_t">Deshpande G, Simmer K. Lipids for parenteral nutrition in neonates. Curr Opin Clin Nutr Metab Care 2011; 14:145.</a></li><li><a class="nounderline abstract_t">Spear ML, Stahl GE, Paul MH, et al. The effect of 15-hour fat infusions of varying dosage on bilirubin binding to albumin. JPEN J Parenter Enteral Nutr 1985; 9:144.</a></li><li><a class="nounderline abstract_t">Kao LC, Cheng MH, Warburton D. Triglycerides, free fatty acids, free fatty acids/albumin molar ratio, and cholesterol levels in serum of neonates receiving long-term lipid infusions: controlled trial of continuous and intermittent regimens. J Pediatr 1984; 104:429.</a></li><li><a class="nounderline abstract_t">Burdine J, Franco-Fuenmayor ME, Huff ML, Shattuck KE. Rapid infusion of fish oil-based lipid emulsions: Is there a risk of fat overload syndrome? A case report of rapid administration. J Clin Pharm Ther 2022; 47:1088.</a></li><li><a class="nounderline abstract_t">Schlegelmilch M, Feder J, Creery D. Inadvertent Acute Lipid Injectable Emulsion Overdose Resulting in Fat Overload Syndrome and Pancreatitis in a Patient with TPN Dependence. JPGN Rep 2022; 3:e146.</a></li><li><a class="nounderline abstract_t">Heyman MB, Storch S, Ament ME. The fat overload syndrome. Report of a case and literature review. Am J Dis Child 1981; 135:628.</a></li><li class="breakAll">Manufacturer's prescribing information for INTRALIPID 20% (May 2023), available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017643s083,018449s050s051,019942s021,020248s027s028lbl.pdf (Accessed on May 30, 2023).</li><li class="breakAll">Manufacturer's prescibing information for SMOFLIPID (May 2023). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/207648s010lbl.pdf (Accessed on May 30, 2023).</li><li class="breakAll">Manufacturer's prescibing information for OMEGAVEN (May 2023). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210589s003lbl.pdf (Accessed on May 30, 2023).</li><li><a class="nounderline abstract_t">Choi YJ, Bae HJ, Lee JY, et al. Analysis of risk factors for lipid intolerance of intravenous fat emulsion in very low birth weight infants. Arch Pharm Res 2015; 38:914.</a></li><li><a class="nounderline abstract_t">Holtrop P, Swails T, Riggs T. Hypertriglyceridemia in extremely low birth weight infants receiving lipid emulsions. J Neonatal Perinatal Med 2015; 8:133.</a></li><li><a class="nounderline abstract_t">Haumont D, Deckelbaum RJ, Richelle M, et al. Plasma lipid and plasma lipoprotein concentrations in low birth weight infants given parenteral nutrition with twenty or ten percent lipid emulsion. J Pediatr 1989; 115:787.</a></li><li><a class="nounderline abstract_t">Boullata JI, Gilbert K, Sacks G, et al. A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing. JPEN J Parenter Enteral Nutr 2014; 38:334.</a></li><li><a class="nounderline abstract_t">Pereira-da-Silva L, Costa A, Pereira L, et al. Early high calcium and phosphorus intake by parenteral nutrition prevents short-term bone strength decline in preterm infants. J Pediatr Gastroenterol Nutr 2011; 52:203.</a></li><li><a class="nounderline abstract_t">Pelegano JF, Rowe JC, Carey DE, et al. Simultaneous infusion of calcium and phosphorus in parenteral nutrition for premature infants: use of physiologic calcium/phosphorus ratio. J Pediatr 1989; 114:115.</a></li><li><a class="nounderline abstract_t">Prestridge LL, Schanler RJ, Shulman RJ, et al. Effect of parenteral calcium and phosphorus therapy on mineral retention and bone mineral content in very low birth weight infants. J Pediatr 1993; 122:761.</a></li><li><a class="nounderline abstract_t">Pelegano JF, Rowe JC, Carey DE, et al. Effect of calcium/phosphorus ratio on mineral retention in parenterally fed premature infants. J Pediatr Gastroenterol Nutr 1991; 12:351.</a></li><li><a class="nounderline abstract_t">Brener Dik PH, Galletti MF, Fernández Jonusas SA, et al. Early hypophosphatemia in preterm infants receiving aggressive parenteral nutrition. J Perinatol 2015; 35:712.</a></li><li><a class="nounderline abstract_t">Boubred F, Herlenius E, Bartocci M, et al. Extremely preterm infants who are small for gestational age have a high risk of early hypophosphatemia and hypokalemia. Acta Paediatr 2015; 104:1077.</a></li><li><a class="nounderline abstract_t">Christmann V, de Grauw AM, Visser R, et al. Early postnatal calcium and phosphorus metabolism in preterm infants. J Pediatr Gastroenterol Nutr 2014; 58:398.</a></li><li><a class="nounderline abstract_t">Bonsante F, Iacobelli S, Latorre G, et al. Initial amino acid intake influences phosphorus and calcium homeostasis in preterm infants--it is time to change the composition of the early parenteral nutrition. PLoS One 2013; 8:e72880.</a></li><li><a class="nounderline abstract_t">Hair AB, Chetta KE, Bruno AM, et al. Delayed Introduction of Parenteral Phosphorus Is Associated with Hypercalcemia in Extremely Preterm Infants. J Nutr 2016; 146:1212.</a></li><li><a class="nounderline abstract_t">Hill SE, Heldman LS, Goo ED, et al. Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution. JPEN J Parenter Enteral Nutr 1996; 20:81.</a></li><li><a class="nounderline abstract_t">Joy J, Silvestri AP, Franke R, et al. Calcium and phosphate compatibility in low-osmolarity parenteral nutrition admixtures intended for peripheral vein administration. JPEN J Parenter Enteral Nutr 2010; 34:46.</a></li><li><a class="nounderline abstract_t">Knowles JB, Cusson G, Smith M, Sitrin MD. Pulmonary deposition of calcium phosphate crystals as a complication of home total parenteral nutrition. JPEN J Parenter Enteral Nutr 1989; 13:209.</a></li><li><a class="nounderline abstract_t">Poole RL, Rupp CA, Kerner JA Jr. Calcium and phosphorus in neonatal parenteral nutrition solutions. JPEN J Parenter Enteral Nutr 1983; 7:358.</a></li><li><a class="nounderline abstract_t">Parikh MJ, Dumas G, Silvestri A, et al. Physical compatibility of neonatal total parenteral nutrient admixtures containing organic calcium and inorganic phosphate salts. Am J Health Syst Pharm 2005; 62:1177.</a></li><li><a class="nounderline abstract_t">Wong JC, McDougal AR, Tofan M, et al. Doubling calcium and phosphate concentrations in neonatal parenteral nutrition solutions using monobasic potassium phosphate. J Am Coll Nutr 2006; 25:70.</a></li><li><a class="nounderline abstract_t">Chessex P, Pineault M, Brisson G, et al. Role of the source of phosphate salt in improving the mineral balance of parenterally fed low birth weight infants. J Pediatr 1990; 116:765.</a></li><li><a class="nounderline abstract_t">Newton DW, Driscoll DF. Calcium and phosphate compatibility: revisited again. Am J Health Syst Pharm 2008; 65:73.</a></li><li><a class="nounderline abstract_t">Bouchoud L, Fonzo-Christe C, Sadeghipour F, Bonnabry P. Maximizing calcium and phosphate content in neonatal parenteral nutrition solutions using organic calcium and phosphate salts. JPEN J Parenter Enteral Nutr 2010; 34:542.</a></li><li><a class="nounderline abstract_t">MacKay M, Anderson C. Physical Compatibility of Sodium Glycerophosphate and Calcium Gluconate in Pediatric Parenteral Nutrition Solutions. JPEN J Parenter Enteral Nutr 2015; 39:725.</a></li><li><a class="nounderline abstract_t">Ikomi C, Cole CR, Vale E, et al. Hypothyroidism and Iodine Deficiency in Children on Chronic Parenteral Nutrition. Pediatrics 2018; 141.</a></li><li><a class="nounderline abstract_t">Zemrani B, McCallum Z, Bines JE. Trace Element Provision in Parenteral Nutrition in Children: One Size Does Not Fit All. Nutrients 2018; 10.</a></li><li><a class="nounderline abstract_t">Vanek VW, Borum P, Buchman A, et al. A Call to Action to Bring Safer Parenteral Micronutrient Products to the U.S. Market. Nutr Clin Pract 2015; 30:559.</a></li><li><a class="nounderline abstract_t">Sutton AM, Harvie A, Cockburn F, et al. Copper deficiency in the preterm infant of very low birthweight. Four cases and a reference range for plasma copper. Arch Dis Child 1985; 60:644.</a></li><li><a class="nounderline abstract_t">Harper JI, Thompson D, Kovar IZ, et al. Zinc deficiency in a preterm neonate with necrotizing enterocolitis. J R Soc Med 1984; 77 Suppl 4:40.</a></li><li><a class="nounderline abstract_t">Marquardt ML, Done SL, Sandrock M, et al. Copper deficiency presenting as metabolic bone disease in extremely low birth weight, short-gut infants. Pediatrics 2012; 130:e695.</a></li><li><a class="nounderline abstract_t">Darlow BA, Austin NC. Selenium supplementation to prevent short-term morbidity in preterm neonates. Cochrane Database Syst Rev 2003; :CD003312.</a></li><li><a class="nounderline abstract_t">Sauberan J, Mercier M, Katheria A. Sources of unintentional manganese delivery in neonatal parenteral nutrition. JPEN J Parenter Enteral Nutr 2022; 46:1283.</a></li><li><a class="nounderline abstract_t">Capone K, Sriram S, Patton T, et al. Effects of Chromium on Glucose Tolerance in Infants Receiving Parenteral Nutrition Therapy. Nutr Clin Pract 2018; 33:426.</a></li><li><a class="nounderline abstract_t">Freitas RG, Nogueira RJ, Antonio MA, et al. Selenium deficiency and the effects of supplementation on preterm infants. Rev Paul Pediatr 2014; 32:126.</a></li><li><a class="nounderline abstract_t">Domellöf M. Nutritional care of premature infants: microminerals. World Rev Nutr Diet 2014; 110:121.</a></li><li><a class="nounderline abstract_t">Friel JK, Andrews WL, Hall MS, et al. Intravenous iron administration to very-low-birth-weight newborns receiving total and partial parenteral nutrition. JPEN J Parenter Enteral Nutr 1995; 19:114.</a></li><li class="breakAll">Vitamin A. In: Nutritional Needs of the Preterm Infant: Scientific Basis and Practical Guidelines, Tsang RC, Lucas A, Uauy R, Zlotkin SH (Eds), Williams &amp; Wilkins, 1993. p.87.</li><li><a class="nounderline abstract_t">Zachman RD. Retinol (vitamin A) and the neonate: special problems of the human premature infant. Am J Clin Nutr 1989; 50:413.</a></li><li><a class="nounderline abstract_t">Baeckert PA, Greene HL, Fritz I, et al. Vitamin concentrations in very low birth weight infants given vitamins intravenously in a lipid emulsion: measurement of vitamins A, D, and E and riboflavin. J Pediatr 1988; 113:1057.</a></li><li><a class="nounderline abstract_t">Porcelli PJ, Greene HL, Adcock EW. Retinol (vitamin A) and riboflavin (vitamin B2) administration and metabolism in very low birth weight infants. Semin Perinatol 1992; 16:170.</a></li><li><a class="nounderline abstract_t">Raju TN, Langenberg P, Bhutani V, Quinn GE. Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J Pediatr 1997; 131:844.</a></li><li><a class="nounderline abstract_t">Phelps DL, Rosenbaum AL, Isenberg SJ, et al. Tocopherol efficacy and safety for preventing retinopathy of prematurity: a randomized, controlled, double-masked trial. Pediatrics 1987; 79:489.</a></li><li><a class="nounderline abstract_t">Puklin JE, Simon RM, Ehrenkranz RA. Influence on retrolental fibroplasia of intramuscular vitamin E administration during respiratory distress syndrome. Ophthalmology 1982; 89:96.</a></li><li><a class="nounderline abstract_t">Ehrenkranz RA, Ablow RC, Warshaw JB. Effect of vitamin E on the development of oxygen-induced lung injury in neonates. Ann N Y Acad Sci 1982; 393:452.</a></li><li><a class="nounderline abstract_t">Saldanha RL, Cepeda EE, Poland RL. The effect of vitamin E prophylaxis on the incidence and severity of bronchopulmonary dysplasia. J Pediatr 1982; 101:89.</a></li><li><a class="nounderline abstract_t">Watts JL, Milner R, Zipursky A, et al. Failure of supplementation with vitamin E to prevent bronchopulmonary dysplasia in infants less than 1,500 g birth weight. Eur Respir J 1991; 4:188.</a></li><li><a class="nounderline abstract_t">Chiswick ML, Johnson M, Woodhall C, et al. Protective effect of vitamin E (DL-alpha-tocopherol) against intraventricular haemorrhage in premature babies. Br Med J (Clin Res Ed) 1983; 287:81.</a></li><li><a class="nounderline abstract_t">Law MR, Wijewardene K, Wald NJ. Is routine vitamin E administration justified in very low-birthweight infants? Dev Med Child Neurol 1990; 32:442.</a></li><li><a class="nounderline abstract_t">Sinha S, Davies J, Toner N, et al. Vitamin E supplementation reduces frequency of periventricular haemorrhage in very preterm babies. Lancet 1987; 1:466.</a></li><li><a class="nounderline abstract_t">Levy R, Herzberg GR, Andrews WL, et al. Thiamine, riboflavin, folate, and vitamin B12 status of low birth weight infants receiving parenteral and enteral nutrition. JPEN J Parenter Enteral Nutr 1992; 16:241.</a></li><li><a class="nounderline abstract_t">Moore MC, Greene HL, Phillips B, et al. Evaluation of a pediatric multiple vitamin preparation for total parenteral nutrition in infants and children. I. Blood levels of water-soluble vitamins. Pediatrics 1986; 77:530.</a></li><li><a class="nounderline abstract_t">Greene HL, Smith R, Pollack P, et al. Intravenous vitamins for very-low-birth-weight infants. J Am Coll Nutr 1991; 10:281.</a></li><li><a class="nounderline abstract_t">Schmidt-Sommerfeld E, Penn D, Wolf H. Carnitine deficiency in premature infants receiving total parenteral nutrition: effect of L-carnitine supplementation. J Pediatr 1983; 102:931.</a></li><li><a class="nounderline abstract_t">Bonner CM, DeBrie KL, Hug G, et al. Effects of parenteral L-carnitine supplementation on fat metabolism and nutrition in premature neonates. J Pediatr 1995; 126:287.</a></li><li><a class="nounderline abstract_t">Kumar M, Kabra NS, Paes B. Role of carnitine supplementation in apnea of prematurity: a systematic review. J Perinatol 2004; 24:158.</a></li><li><a class="nounderline abstract_t">Cairns PA, Stalker DJ. Carnitine supplementation of parenterally fed neonates. Cochrane Database Syst Rev 2000; :CD000950.</a></li><li><a class="nounderline abstract_t">Pande S, Brion LP, Campbell DE, et al. Lack of effect of L-carnitine supplementation on weight gain in very preterm infants. J Perinatol 2005; 25:470.</a></li><li><a class="nounderline abstract_t">Shah PS, Ng E, Sinha AK. Heparin for prolonging peripheral intravenous catheter use in neonates. Cochrane Database Syst Rev 2005; :CD002774.</a></li><li><a class="nounderline abstract_t">Shah PS, Kalyn A, Satodia P, et al. A randomized, controlled trial of heparin versus placebo infusion to prolong the usability of peripherally placed percutaneous central venous catheters (PCVCs) in neonates: the HIP (Heparin Infusion for PCVC) study. Pediatrics 2007; 119:e284.</a></li><li><a class="nounderline abstract_t">Birch P, Ogden S, Hewson M. A randomised, controlled trial of heparin in total parenteral nutrition to prevent sepsis associated with neonatal long lines: the Heparin in Long Line Total Parenteral Nutrition (HILLTOP) trial. Arch Dis Child Fetal Neonatal Ed 2010; 95:F252.</a></li><li><a class="nounderline abstract_t">Uslu S, Ozdemir H, Comert S, et al. The effect of low-dose heparin on maintaining peripherally inserted percutaneous central venous catheters in neonates. J Perinatol 2010; 30:794.</a></li><li><a class="nounderline abstract_t">Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, et al. Early insulin therapy in very-low-birth-weight infants. N Engl J Med 2008; 359:1873.</a></li><li><a class="nounderline abstract_t">Beardsall K, Ogilvy-Stuart AL, Frystyk J, et al. Early elective insulin therapy can reduce hyperglycemia and increase insulin-like growth factor-I levels in very low birth weight infants. J Pediatr 2007; 151:611.</a></li><li><a class="nounderline abstract_t">Ainsworth S, McGuire W. Percutaneous central venous catheters versus peripheral cannulae for delivery of parenteral nutrition in neonates. Cochrane Database Syst Rev 2015; :CD004219.</a></li><li><a class="nounderline abstract_t">Bethune K, Allwood M, Grainger C, et al. Use of filters during the preparation and administration of parenteral nutrition: position paper and guidelines prepared by a British pharmaceutical nutrition group working party. Nutrition 2001; 17:403.</a></li><li><a class="nounderline abstract_t">Hays SP, Smith EO, Sunehag AL. Hyperglycemia is a risk factor for early death and morbidity in extremely low birth-weight infants. Pediatrics 2006; 118:1811.</a></li><li><a class="nounderline abstract_t">Stensvold HJ, Strommen K, Lang AM, et al. Early Enhanced Parenteral Nutrition, Hyperglycemia, and Death Among Extremely Low-Birth-Weight Infants. JAMA Pediatr 2015; 169:1003.</a></li><li><a class="nounderline abstract_t">Alsweiler JM, Harding JE, Bloomfield FH. Neonatal hyperglycaemia increases mortality and morbidity in preterm lambs. Neonatology 2013; 103:83.</a></li><li><a class="nounderline abstract_t">Arsenault D, Brenn M, Kim S, et al. A.S.P.E.N. Clinical Guidelines: hyperglycemia and hypoglycemia in the neonate receiving parenteral nutrition. JPEN J Parenter Enteral Nutr 2012; 36:81.</a></li><li><a class="nounderline abstract_t">Alsweiler JM, Harding JE, Bloomfield FH. Tight glycemic control with insulin in hyperglycemic preterm babies: a randomized controlled trial. Pediatrics 2012; 129:639.</a></li><li><a class="nounderline abstract_t">Shouman B, Abdel-Hady H, Badr RI, et al. Dose of intravenous lipids and rate of bacterial clearance in preterm infants with blood stream infections. Eur J Pediatr 2012; 171:811.</a></li><li><a class="nounderline abstract_t">Hammerman C, Aramburo MJ. Decreased lipid intake reduces morbidity in sick premature neonates. J Pediatr 1988; 113:1083.</a></li><li><a class="nounderline abstract_t">Lewandowski AJ, Lazdam M, Davis E, et al. Short-term exposure to exogenous lipids in premature infants and long-term changes in aortic and cardiac function. Arterioscler Thromb Vasc Biol 2011; 31:2125.</a></li><li><a class="nounderline abstract_t">Rayyan M, Devlieger H, Jochum F, Allegaert K. Short-term use of parenteral nutrition with a lipid emulsion containing a mixture of soybean oil, olive oil, medium-chain triglycerides, and fish oil: a randomized double-blind study in preterm infants. JPEN J Parenter Enteral Nutr 2012; 36:81S.</a></li><li><a class="nounderline abstract_t">Kapoor V, Glover R, Malviya MN. Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm infants. Cochrane Database Syst Rev 2015; :CD009172.</a></li><li class="breakAll">Shoji H, Shimizu T. Parenteral soybean oil lipid emulsion in very low birth weight (VLBW) in intensive care. In: Diet and Nutrition in Critical Care, Rajendram R, Preedy VR, Patel VB (Eds), Springer, 2015. p.1807.</li><li class="breakAll">Bohrer D. Aluminum in subjects receiving parenteral nutrition. In: Diet and Nutrition in Critical Care, Rajendram R, Preedy VR, Patel VB (Eds), Springer, 2015. p.2049.</li><li><a class="nounderline abstract_t">Bishop NJ, Morley R, Day JP, Lucas A. Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions. N Engl J Med 1997; 336:1557.</a></li><li><a class="nounderline abstract_t">Fewtrell MS, Bishop NJ, Edmonds CJ, et al. Aluminum exposure from parenteral nutrition in preterm infants: bone health at 15-year follow-up. Pediatrics 2009; 124:1372.</a></li><li><a class="nounderline abstract_t">Poole RL, Hintz SR, Mackenzie NI, Kerner JA Jr. Aluminum exposure from pediatric parenteral nutrition: meeting the new FDA regulation. JPEN J Parenter Enteral Nutr 2008; 32:242.</a></li><li><a class="nounderline abstract_t">Costakos DT. Of lobsters, electronic medical records, and neonatal total parenteral nutrition. Pediatrics 2006; 117:e328.</a></li><li><a class="nounderline abstract_t">Bolisetty S, Osborn D, Sinn J, et al. Standardised neonatal parenteral nutrition formulations - an Australasian group consensus 2012. BMC Pediatr 2014; 14:48.</a></li><li><a class="nounderline abstract_t">Bolisetty S, Pharande P, Nirthanakumaran L, et al. Improved nutrient intake following implementation of the consensus standardised parenteral nutrition formulations in preterm neonates--a before-after intervention study. BMC Pediatr 2014; 14:309.</a></li><li><a class="nounderline abstract_t">Evering VH, Andriessen P, Duijsters CE, et al. The Effect of Individualized Versus Standardized Parenteral Nutrition on Body Weight in Very Preterm Infants. J Clin Med Res 2017; 9:339.</a></li><li><a class="nounderline abstract_t">Dice JE, Burckart GJ, Woo JT, Helms RA. Standardized versus pharmacist-monitored individualized parenteral nutrition in low-birth-weight infants. Am J Hosp Pharm 1981; 38:1487.</a></li><li class="breakAll">Dömellof D, Wackernagel D. Meeting nutritional goals computer-aided prescribing of enteral and parenteral nutrition. In: Perinatal Growth and Nutrition, 1st ed, Griffin IJ (Ed), Taylor and Francis, 2014.</li><li><a class="nounderline abstract_t">Franco KA, O'Mara K. Impact of Computerized Provider Order Entry on Total Parenteral Nutrition in the Neonatal Intensive Care Unit. J Pediatr Pharmacol Ther 2016; 21:339.</a></li><li><a class="nounderline abstract_t">Puangco MA, Nguyen HL, Sheridan MJ. Computerized PN ordering optimizes timely nutrition therapy in a neonatal intensive care unit. J Am Diet Assoc 1997; 97:258.</a></li><li><a class="nounderline abstract_t">Ayers P, Adams S, Boullata J, et al. A.S.P.E.N. parenteral nutrition safety consensus recommendations. JPEN J Parenter Enteral Nutr 2014; 38:296.</a></li></ol></div><div id="topicVersionRevision">Topic 5026 Version 59.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4965871" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Growth and development of an infant receiving all nutrients exclusively by vein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37610837" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Guidelines for parenteral nutrition in preterm infants: The American Society for Parenteral and Enteral Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37610837" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Guidelines for parenteral nutrition in preterm infants: The American Society for Parenteral and Enteral Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8433885" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effect of the quality of infused energy on substrate utilization in the newborn receiving total parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1907091" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Protein-metabolism kinetics and energy-substrate utilization in infants fed parenteral solutions with different glucose-fat ratios.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1898751" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Total parenteral nutrition in the newborn infant: energy substrates and respiratory gas exchange.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23446896" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Early parenteral nutrition and growth outcomes in preterm infants: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23446896" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Early parenteral nutrition and growth outcomes in preterm infants: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18589451" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Metabolic responses to early and high protein supplementation in a randomized trial evaluating the prevention of hyperkalemia in extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23941670" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Targeting 2.5 versus 4 g/kg/day of amino acids for extremely low birth weight infants: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30100107" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Amino acids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34352778" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Recommended Nutrient Intake Levels for Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36322845" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Early Amino Acids in Extremely Preterm Infants and Neurodisability at 2 Years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6423797" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Total parenteral nutrition in sick preterm infants: effects of cysteine supplementation with nitrogen intakes of 240 and 400 mg/kg/day.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7815670" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Amino acid solutions for premature neonates during the first week of life: the role of N-acetyl-L-cysteine and N-acetyl-L-tyrosine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17054219" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cysteine, cystine or N-acetylcysteine supplementation in parenterally fed neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1908633" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cysteine usage increases the need for acetate in neonates who receive total parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15121931" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27089158" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Glutamine supplementation to prevent morbidity and mortality in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23071202" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effects of glutamine on brain development in very preterm children at school age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/824608" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rapid onset of essential fatty acid deficiency in the newborn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1957817" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intravenous infusion of lipid for the prevention of essential fatty acid deficiency in premature infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1919895" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Introduction of intravenous lipid administration on the first day of life in the very low birth weight neonate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15846747" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Early introduction of lipids to parenterally-fed preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21192257" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Lipids for parenteral nutrition in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4039374" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The effect of 15-hour fat infusions of varying dosage on bilirubin binding to albumin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6368776" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Triglycerides, free fatty acids, free fatty acids/albumin molar ratio, and cholesterol levels in serum of neonates receiving long-term lipid infusions: controlled trial of continuous and intermittent regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35304749" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rapid infusion of fish oil-based lipid emulsions: Is there a risk of fat overload syndrome? A case report of rapid administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37168746" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Inadvertent Acute Lipid Injectable Emulsion Overdose Resulting in Fat Overload Syndrome and Pancreatitis in a Patient with TPN Dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6787913" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The fat overload syndrome. Report of a case and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6787913" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The fat overload syndrome. Report of a case and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6787913" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The fat overload syndrome. Report of a case and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6787913" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The fat overload syndrome. Report of a case and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24849035" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Analysis of risk factors for lipid intolerance of intravenous fat emulsion in very low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26410437" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hypertriglyceridemia in extremely low birth weight infants receiving lipid emulsions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2809914" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Plasma lipid and plasma lipoprotein concentrations in low birth weight infants given parenteral nutrition with twenty or ten percent lipid emulsion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24531708" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A.S.P.E.N. clinical guidelines: parenteral nutrition ordering, order review, compounding, labeling, and dispensing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21240015" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Early high calcium and phosphorus intake by parenteral nutrition prevents short-term bone strength decline in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2491886" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Simultaneous infusion of calcium and phosphorus in parenteral nutrition for premature infants: use of physiologic calcium/phosphorus ratio.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8496758" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of parenteral calcium and phosphorus therapy on mineral retention and bone mineral content in very low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1649288" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effect of calcium/phosphorus ratio on mineral retention in parenterally fed premature infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26067471" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Early hypophosphatemia in preterm infants receiving aggressive parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26100071" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Extremely preterm infants who are small for gestational age have a high risk of early hypophosphatemia and hypokalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24253367" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Early postnatal calcium and phosphorus metabolism in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23977367" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Initial amino acid intake influences phosphorus and calcium homeostasis in preterm infants--it is time to change the composition of the early parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27146915" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Delayed Introduction of Parenteral Phosphorus Is Associated with Hypercalcemia in Extremely Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8788269" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19846668" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Calcium and phosphate compatibility in low-osmolarity parenteral nutrition admixtures intended for peripheral vein administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2496252" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pulmonary deposition of calcium phosphate crystals as a complication of home total parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6413711" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Calcium and phosphorus in neonatal parenteral nutrition solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15914878" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Physical compatibility of neonatal total parenteral nutrient admixtures containing organic calcium and inorganic phosphate salts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537340" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Doubling calcium and phosphate concentrations in neonatal parenteral nutrition solutions using monobasic potassium phosphate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2109792" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Role of the source of phosphate salt in improving the mineral balance of parenterally fed low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18159044" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Calcium and phosphate compatibility: revisited again.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20852183" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Maximizing calcium and phosphate content in neonatal parenteral nutrition solutions using organic calcium and phosphate salts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24696096" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Physical Compatibility of Sodium Glycerophosphate and Calcium Gluconate in Pediatric Parenteral Nutrition Solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29496904" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hypothyroidism and Iodine Deficiency in Children on Chronic Parenteral Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30469420" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Trace Element Provision in Parenteral Nutrition in Children: One Size Does Not Fit All.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26113560" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A Call to Action to Bring Safer Parenteral Micronutrient Products to the U.S. Market.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4026360" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Copper deficiency in the preterm infant of very low birthweight. Four cases and a reference range for plasma copper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6439869" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Zinc deficiency in a preterm neonate with necrotizing enterocolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22869833" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Copper deficiency presenting as metabolic bone disease in extremely low birth weight, short-gut infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583967" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Selenium supplementation to prevent short-term morbidity in preterm neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34919287" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Sources of unintentional manganese delivery in neonatal parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28570117" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effects of Chromium on Glucose Tolerance in Infants Receiving Parenteral Nutrition Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24676200" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Selenium deficiency and the effects of supplementation on preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24751625" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Nutritional care of premature infants: microminerals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7609274" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Intravenous iron administration to very-low-birth-weight newborns receiving total and partial parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7609274" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Intravenous iron administration to very-low-birth-weight newborns receiving total and partial parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2672772" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Retinol (vitamin A) and the neonate: special problems of the human premature infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3142982" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Vitamin concentrations in very low birth weight infants given vitamins intravenously in a lipid emulsion: measurement of vitamins A, D, and E and riboflavin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1514108" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Retinol (vitamin A) and riboflavin (vitamin B2) administration and metabolism in very low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427888" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3547300" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Tocopherol efficacy and safety for preventing retinopathy of prematurity: a randomized, controlled, double-masked trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7041039" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Influence on retrolental fibroplasia of intramuscular vitamin E administration during respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6756261" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effect of vitamin E on the development of oxygen-induced lung injury in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7045320" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The effect of vitamin E prophylaxis on the incidence and severity of bronchopulmonary dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2044736" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Failure of supplementation with vitamin E to prevent bronchopulmonary dysplasia in infants less than 1,500 g birth weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6407714" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Protective effect of vitamin E (DL-alpha-tocopherol) against intraventricular haemorrhage in premature babies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2191890" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Is routine vitamin E administration justified in very low-birthweight infants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2881038" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Vitamin E supplementation reduces frequency of periventricular haemorrhage in very preterm babies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1501354" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Thiamine, riboflavin, folate, and vitamin B12 status of low birth weight infants receiving parenteral and enteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3083396" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Evaluation of a pediatric multiple vitamin preparation for total parenteral nutrition in infants and children. I. Blood levels of water-soluble vitamins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1910062" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Intravenous vitamins for very-low-birth-weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6406654" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Carnitine deficiency in premature infants receiving total parenteral nutrition: effect of L-carnitine supplementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7844680" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Effects of parenteral L-carnitine supplementation on fat metabolism and nutrition in premature neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14985774" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Role of carnitine supplementation in apnea of prematurity: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11034690" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Carnitine supplementation of parenterally fed neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15858602" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Lack of effect of L-carnitine supplementation on weight gain in very preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235300" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Heparin for prolonging peripheral intravenous catheter use in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17200252" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A randomized, controlled trial of heparin versus placebo infusion to prolong the usability of peripherally placed percutaneous central venous catheters (PCVCs) in neonates: the HIP (Heparin Infusion for PCVC) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20530110" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A randomised, controlled trial of heparin in total parenteral nutrition to prevent sepsis associated with neonatal long lines: the Heparin in Long Line Total Parenteral Nutrition (HILLTOP) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20376059" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The effect of low-dose heparin on maintaining peripherally inserted percutaneous central venous catheters in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18971490" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Early insulin therapy in very-low-birth-weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18035140" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Early elective insulin therapy can reduce hyperglycemia and increase insulin-like growth factor-I levels in very low birth weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26439610" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Percutaneous central venous catheters versus peripheral cannulae for delivery of parenteral nutrition in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11377134" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Use of filters during the preparation and administration of parenteral nutrition: position paper and guidelines prepared by a British pharmaceutical nutrition group working party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17079549" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Hyperglycemia is a risk factor for early death and morbidity in extremely low birth-weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26348113" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Early Enhanced Parenteral Nutrition, Hyperglycemia, and Death Among Extremely Low-Birth-Weight Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23128645" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Neonatal hyperglycaemia increases mortality and morbidity in preterm lambs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22179520" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A.S.P.E.N. Clinical Guidelines: hyperglycemia and hypoglycemia in the neonate receiving parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22430450" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Tight glycemic control with insulin in hyperglycemic preterm babies: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22105872" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Dose of intravenous lipids and rate of bacterial clearance in preterm infants with blood stream infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3142984" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Decreased lipid intake reduces morbidity in sick premature neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21817105" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Short-term exposure to exogenous lipids in premature infants and long-term changes in aortic and cardiac function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22237883" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Short-term use of parenteral nutrition with a lipid emulsion containing a mixture of soybean oil, olive oil, medium-chain triglycerides, and fish oil: a randomized double-blind study in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26630252" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26630252" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26630252" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Alternative lipid emulsions versus pure soy oil based lipid emulsions for parenterally fed preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164811" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858156" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Aluminum exposure from parenteral nutrition in preterm infants: bone health at 15-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443135" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Aluminum exposure from pediatric parenteral nutrition: meeting the new FDA regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16452339" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Of lobsters, electronic medical records, and neonatal total parenteral nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24548745" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Standardised neonatal parenteral nutrition formulations - an Australasian group consensus 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25514973" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Improved nutrient intake following implementation of the consensus standardised parenteral nutrition formulations in preterm neonates--a before-after intervention study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28270894" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The Effect of Individualized Versus Standardized Parenteral Nutrition on Body Weight in Very Preterm Infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6794364" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Standardized versus pharmacist-monitored individualized parenteral nutrition in low-birth-weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6794364" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Standardized versus pharmacist-monitored individualized parenteral nutrition in low-birth-weight infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27713674" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Impact of Computerized Provider Order Entry on Total Parenteral Nutrition in the Neonatal Intensive Care Unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9060941" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Computerized PN ordering optimizes timely nutrition therapy in a neonatal intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24280129" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : A.S.P.E.N. parenteral nutrition safety consensus recommendations.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
